55 related articles for article (PubMed ID: 8709093)
21. Mutational analysis of the potential phosphorylation sites for protein kinase C on the CCK(A) receptor.
Smeets RL; Fouraux MA; Pouwels W; van Emst-de Vries SE; Ronken E; De Pont JJ; Willems PH
Br J Pharmacol; 1998 Jul; 124(5):935-45. PubMed ID: 9692779
[TBL] [Abstract][Full Text] [Related]
22. Elimination of a cholecystokinin receptor agonist 'trigger' in an effort to develop positive allosteric modulators without intrinsic agonist activity.
Desai AJ; Henke BR; Miller LJ
Bioorg Med Chem Lett; 2015 May; 25(9):1849-55. PubMed ID: 25862198
[TBL] [Abstract][Full Text] [Related]
23. 3-[5-(3,4-Dichloro-phenyl)-1-(4-methoxy-phenyl)-1H-pyrazol-3-yl]-2-m-tolyl-propionate (JNJ-17156516), a novel, potent, and selective cholecystokinin 1 receptor antagonist: in vitro and in vivo pharmacological comparison with dexloxiglumide.
Morton MF; Barrett TD; Yan W; Freedman JM; Lagaud G; Prendergast CE; Moreno V; Pyati J; Figueroa K; Li L; Wu X; Rizzolio M; Breitenbucher JG; McClure K; Shankley NP
J Pharmacol Exp Ther; 2007 Nov; 323(2):562-9. PubMed ID: 17684117
[TBL] [Abstract][Full Text] [Related]
24. Cholecystokinin (CCK) down regulates PGE2 and PGI2 release in inflamed Guinea pig gallbladder smooth muscle cell cultures.
Myers SI; Bartula LL; Colvin MP; Parkman HP
Prostaglandins Leukot Essent Fatty Acids; 2005 Aug; 73(2):121-6. PubMed ID: 16023335
[TBL] [Abstract][Full Text] [Related]
25. 2-Substituted piperazine-derived imidazole carboxamides as potent and selective CCK1R agonists for the treatment of obesity.
Berger R; Zhu C; Hansen AR; Harper B; Chen Z; Holt TG; Hubert J; Lee SJ; Pan J; Qian S; Reitman ML; Strack AM; Weingarth DT; Wolff M; Macneil DJ; Weber AE; Edmondson SD
Bioorg Med Chem Lett; 2008 Sep; 18(17):4833-7. PubMed ID: 18684621
[TBL] [Abstract][Full Text] [Related]
26. The basis for progesterone impairment of gallbladder contractility in male guinea pigs in vitro.
Kiaii B; Xu QW; Shaffer EA
J Surg Res; 1998 Oct; 79(2):97-102. PubMed ID: 9758722
[TBL] [Abstract][Full Text] [Related]
27. Concise approach toward tetrazolo[1,5-a][1,4]benzodiazepines via a novel multicomponent isocyanide-based condensation.
Borisov RS; Polyakov AI; Medvedeva LA; Khrustalev VN; Guranova NI; Voskressensky LG
Org Lett; 2010 Sep; 12(17):3894-7. PubMed ID: 20698482
[TBL] [Abstract][Full Text] [Related]
28. The vagal afferent pathway does not play a major role in the induction of satiety by intestinal fatty acid in rats.
Ogawa N; Yamaguchi H; Shimbara T; Toshinai K; Kakutani M; Yonemori F; Nakazato M
Neurosci Lett; 2008 Mar; 433(1):38-42. PubMed ID: 18248897
[TBL] [Abstract][Full Text] [Related]
29. Optimization of 1,3,4-benzotriazepine-based CCK(2) antagonists to obtain potent, orally active inhibitors of gastrin-mediated gastric acid secretion.
McDonald IM; Black JW; Buck IM; Dunstone DJ; Griffin EP; Harper EA; Hull RA; Kalindjian SB; Lilley EJ; Linney ID; Pether MJ; Roberts SP; Shaxted ME; Spencer J; Steel KI; Sykes DA; Walker MK; Watt GF; Wright L; Wright PT; Xun W
J Med Chem; 2007 Jun; 50(13):3101-12. PubMed ID: 17536796
[TBL] [Abstract][Full Text] [Related]
30. Effects of oral preload, CCK or bombesin administration on short term food intake of melanocortin 4-receptor knockout (MC4RKO) mice.
Vaughan CH; Haskell-Luevano C; Andreasen A; Rowland NE
Peptides; 2006 Dec; 27(12):3226-33. PubMed ID: 16963158
[TBL] [Abstract][Full Text] [Related]
31. Combinatorial solid phase synthesis of multiply substituted 1,4-benzodiazepines and affinity studies on the CCK2 receptor (part 1).
Lattmann E; Billington DC; Poyner DR; Arayarat P; Howitt SB; Lawrence S; Offel M
Drug Des Discov; 2002; 18(1):9-21. PubMed ID: 12375632
[TBL] [Abstract][Full Text] [Related]
32. Dorsal hindbrain 5-HT3 receptors participate in control of meal size and mediate CCK-induced satiation.
Hayes MR; Covasa M
Brain Res; 2006 Aug; 1103(1):99-107. PubMed ID: 16793030
[TBL] [Abstract][Full Text] [Related]
33. Peptide/benzodiazepine hybrids as ligands of CCK(A) and CCK(B) receptors.
Escherich A; Lutz J; Escrieut C; Fourmy D; van Neuren AS; Müller G; Schafferhans A; Klebe G; Moroder L
Biopolymers; 2000-2001; 56(2):55-76. PubMed ID: 11592053
[TBL] [Abstract][Full Text] [Related]
34. Intermolecular interactions between peptidic and nonpeptidic agonists and the third extracellular loop of the cholecystokinin 1 receptor.
Giragossian C; Sugg EE; Szewczyk JR; Mierke DF
J Med Chem; 2003 Jul; 46(16):3476-82. PubMed ID: 12877585
[TBL] [Abstract][Full Text] [Related]
35. Synthesis and antitumour activity of a series of cyclic amidines of 2,3-dihydro-1H-1,5-benzodiazepines.
Janciene R; Kosychova L; Bukelskiene V; Domkus V; Stumbreviciūte Z; Ragaleviciene V; Puodziūnaite BD
Arzneimittelforschung; 2002; 52(6):475-81. PubMed ID: 12109049
[TBL] [Abstract][Full Text] [Related]
36. Unique pharmacologic profile of triazolobenzodiazepines.
Lesar TS
Clin Pharm; 1986 Jun; 5(6):468-9. PubMed ID: 3720215
[No Abstract] [Full Text] [Related]
37. Oleylethanolamide: a lipid mediator involved in gut satiety mechanisms.
Inui A
J Gastroenterol Hepatol; 2004 Jan; 19(1):117. PubMed ID: 14675257
[No Abstract] [Full Text] [Related]
38. The pharmacology of benzodiazepines: comments on terminology and sources of data.
Greenblatt DJ
Psychopharmacology (Berl); 1995 Mar; 118(2):119; discussion 120-1. PubMed ID: 7617796
[No Abstract] [Full Text] [Related]
39. A review of benzodiazepines.
Bergman SA; Wynn RL
Compendium; 1987; 8(7):520, 522-6. PubMed ID: 3315207
[No Abstract] [Full Text] [Related]
40. Molecular basis for benzodiazepine agonist action at the type 1 cholecystokinin receptor.
Harikumar KG; Cawston EE; Lam PCH; Patil A; Orry A; Henke BR; Abagyan R; Christopoulos A; Sexton PM; Miller LJ
J Biol Chem; 2013 Jul; 288(29):21082-21095. PubMed ID: 23754289
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
